NeuroCycle Therapeutics has been awarded a grant from the Helping to End Addiction Long-termsm Initiative, or the NIH HEAL Initiativesm, to advance development of its novel non-addictive treatment of chronic musculoskeletal pain.
NCT specializes in targeting specific receptor subtypes within the central nervous system to fight central sensitization disorders including chronic pain. This enables its next generation products to produce maximum efficacy while minimizing side effects, all without the risk of misuse.
NCT's award is one of 375 grant awards across 41 states made by the National Institutes of Health in fiscal year 2019. The NIH HEAL Initiativesm is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"It's clear that a multi-pronged scientific approach is needed to reduce the risks of opioids, accelerate development of effective non-opioid therapies for pain and provide more flexible and effective options for treating addiction to opioids," said NIH Director Francis S. Collins, M.D., Ph.D., who launched the initiative. "This unprecedented investment in the NIH HEAL Initiative demonstrates the commitment to reversing this devastating crisis."
NCT specializes in targeting specific receptor subtypes within the central nervous system to fight central sensitization disorders including chronic pain. This enables its next generation products to produce maximum efficacy while minimizing side effects, all without the risk of misuse.